Insider Buying: InspireMD (NYSE:NSPR) Director Buys 10,000 Shares of Stock

by · The Cerbat Gem

InspireMD, Inc. (NYSE:NSPR – Get Free Report) Director Paul Stuka purchased 10,000 shares of the stock in a transaction on Monday, May 11th. The shares were purchased at an average cost of $1.19 per share, with a total value of $11,900.00. Following the transaction, the director owned 632,871 shares in the company, valued at $753,116.49. This trade represents a 1.61% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Paul Stuka also recently made the following trade(s):

  • On Friday, May 8th, Paul Stuka purchased 65,626 shares of InspireMD stock. The shares were purchased at an average cost of $1.16 per share, with a total value of $76,126.16.
  • On Thursday, May 7th, Paul Stuka purchased 6,378 shares of InspireMD stock. The shares were purchased at an average cost of $1.15 per share, with a total value of $7,334.70.
  • On Wednesday, May 6th, Paul Stuka purchased 1,517 shares of InspireMD stock. The shares were purchased at an average cost of $1.12 per share, with a total value of $1,699.04.

InspireMD Price Performance

NSPR traded down $0.05 on Tuesday, reaching $1.20. 160,686 shares of the stock were exchanged, compared to its average volume of 180,397. The company’s 50-day moving average price is $1.47 and its 200 day moving average price is $1.73. InspireMD, Inc. has a fifty-two week low of $1.02 and a fifty-two week high of $2.93. The firm has a market capitalization of $56.27 million, a PE ratio of -1.60 and a beta of 0.82.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on NSPR shares. Maxim Group initiated coverage on InspireMD in a research note on Monday, February 2nd. They set a “buy” rating and a $6.00 price objective for the company. Piper Sandler reiterated an “overweight” rating and issued a $3.00 price objective (down from $4.00) on shares of InspireMD in a report on Tuesday, May 5th. Loop Capital set a $5.00 price objective on InspireMD in a report on Tuesday, February 24th. Finally, Lake Street Capital set a $4.00 price target on InspireMD in a research note on Monday, May 4th. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $4.50.

Read Our Latest Analysis on NSPR

Institutional Trading of InspireMD

Large investors have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in shares of InspireMD during the fourth quarter worth $30,000. Virtu Financial LLC purchased a new position in shares of InspireMD during the fourth quarter worth about $31,000. Creative Planning purchased a new position in shares of InspireMD during the second quarter worth about $44,000. Uniting Wealth Partners LLC purchased a new position in shares of InspireMD during the third quarter worth about $51,000. Finally, Legato Capital Management LLC purchased a new position in shares of InspireMD during the fourth quarter worth about $48,000. Hedge funds and other institutional investors own 44.78% of the company’s stock.

About InspireMD

(Get Free Report)

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.

Read More